Clinical Profile


Clinical efficacy across a range of patient types1


Safety Considerations1

ULTANE can cause malignant hyperthermia. ULTANE is contraindicated in patients with known senstivity to any of its product ingredients or to other halogenated agents, or in patients with known or suspected susceptibility to malignant hperthermia.

Adverse events reported by ≥5% of the surgical patients receiving ULTANE during clinical trials during induction included: bradycardia, tachycardia, agitation, laryngospasm, airway obstruction, breathholding, and increased cough; during maintenance and emergence: shivering, hypotension, bradycardia, somnolence, agitation, nausea, vomiting and increased cough were reported.